SiNtx Technologies, Inc. SINT 深 滬
交易中 12-24 10:04:39 美东时间
3.59
-0.050
-1.37%
華盛通- 最 高3.64
- 今 開3.64
- 成交量 401股
- 最 低 3.59
- 昨 收 3.64
- 總市值 1382.87万
- 52周最高 7.36
- 市盈率 靜 --
- 換手率 0.01%
- 52周最低 1.71
- 委 比 -81.82%
- 總股本 385.20万
- 歷史最高 209400.00
- 量 比 0.22
- 振 幅 1.37%
- 歷史最低 1.71
- 每 手 1
- 風險率 0.70%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅2566.67%！Ascendiant Capital上调GRI Bio目标价至36美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从35美元升至36美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.75美元升至8美元
12-09 10:32
SINTX Technologies to Participate in Sidoti & Company Investor Conference
SINTX Technologies, Inc. (NASDAQ: SINT) announced that its management will present at Sidoti & Company’s Year End Virtual Investor Conference on December 10-11, 2025. The presentation will take place on December 10, 2025, at 3:15 P.M. ET and can be viewed via the provided webcast link. Investors can schedule one-on-one meetings with SINTX’s management team by emailing Sintx@kcsa.com. SINTX is an advanced ceramics company specializing in silicon n...
12-08 14:00
SINTX Technologies Strikes Supply Agreement With Evonik To Produce Proprietary Silicon Nitride-PEEK Compound
SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics and biomaterials company, today announced that it has signed a supply agreement with Evonik Corporation ("EVONIK"), a global leader
12-01 21:33
SINTX Technologies Q3 EPS $(1.19) Misses $(0.51) Estimate, Sales $208.000K Miss $300.000K Estimate
SINTX Technologies (NASDAQ:SINT) reported quarterly losses of $(1.19) per share which missed the analyst consensus estimate of $(0.51) by 133.33 percent. This is a 82.9 percent increase over losses of $(6.96) per share
11-13 21:14
SINTX Technologies Receives FDA 510(K) Clearance For Its SINAPTIC Foot & Ankle Osteotomy Wedge System
SALT LAKE CITY, Utah, Nov. 13, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics and biomaterials company focused on silicon-nitride–based medical
11-13 21:08
SINTX Technologies Launches OsseoSculpt
Clinical evaluation of the product by design surgeons completed, driving early commercial momentum
11-03 21:05
SINTX Technologies Announces Launch of OsseoSculpt™ an Advanced Biologic for Use with SINAPTIC® Foot & Ankle Osteotomy Wedge System
SINTX Technologies announced a private-label agreement to supply OsseoSculpt™, a next-generation biologic, which complements its FDA-cleared SINAPTIC® Foot & Ankle Osteotomy Wedge System. Following successful evaluations by design surgeons, SINTX recorded its first commercial revenue from OsseoSculpt™ in Q3 2025. The product features a nanocrystalline HCA surface designed to enhance osteoconduction and is marketed alongside the SINAPTIC system to...
11-03 13:00
SINTX Technologies Receives FDA Clearance for SINAPTIC® Foot & Ankle Implant System
SINTX Technologies announced FDA clearance for its SINAPTIC® Foot & Ankle Osteotomy Wedge System, enabling entry into the $5.4 billion U.S. foot and ankle device market. The system combines silicon nitride biomaterial with surgeon-informed designs, offering advantages like osseointegration, bacteriostasis, hydrophilicity, and superior imaging visibility. SINTX plans a U.S. launch in Q1 2026, leveraging domestic manufacturing to drive growth and e...
10-20 11:00
UPDATE: SINTX Strengthens Infection-Prevention Portfolio with Newly Allowed U.S. Patent Covering $30 Billion Antipathogenic Addressable Market
<p>SINTX Technologies has been granted a U.S. patent for its antipathogenic fabric technology's method claims, enhancing its IP portfolio to protect both material composition and manufacturing processes. This dual coverage strengthens competitive advantage and expands licensing opportunities across medical textiles, filtration, and PPE. CEO Eric Olson highlighted the milestone as reinforcing the company's leadership in infection-resistant materia...
10-16 11:00
SINTX Technologies Expands Patent Protections for Antipathogenic Fabrics, Strengthening Biomedical IP Portfolio
SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics innovator specializing in biomedical applications of silicon nitride (Si₃N₄), today announced that the United States Patent and
10-14 19:16
